September 18, 2014 2:23 AM ET

Biotechnology

Company Overview of Five Prime Therapeutics, Inc.

Company Overview

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FP-1039/GSK3052230, a protein therapeutic, which is in Phase 1b clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, a Phase 1 clinical trial stage antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumo...

Two Corporate Drive

South San Francisco, CA 94080

United States

Founded in 2001

105 Employees

Phone:

415-365-5600

Fax:

415-365-5601

Key Executives for Five Prime Therapeutics, Inc.

Founder
Age: 65
Total Annual Compensation: $525.0K
Chief Business Officer
Age: 45
Total Annual Compensation: $362.8K
Chief Medical Officer and Senior Vice President
Age: 56
Total Annual Compensation: $350.0K
Senior Vice President
Age: 43
Total Annual Compensation: $311.9K
Compensation as of Fiscal Year 2013.

Five Prime Therapeutics, Inc. Key Developments

GlaxoSmithKline Exercises Option for a Commercial License to a Novel Muscle Disease Target

Five Prime Therapeutics, Inc. announced that GlaxoSmithKline (GSK) has exercised its option to obtain an exclusive, worldwide license to products containing or directed to an undisclosed muscle disease target that Five Prime discovered using its proprietary library of human extracellular proteins and target screening and discovery capabilities. By exercising its option, GSK will receive exclusive rights to develop and commercialize products globally, at its own cost and expense, that incorporate or are directed to the selected target. Five Prime will receive a payment of $1.5 million in connection with the option exercise and is entitled to receive up to $122.5 million in preclinical, development and commercial-related milestone payments and royalties in the low- to mid-single-digit range on net sales of products related to the target.

Five Prime Therapeutics, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 05:15 PM

Five Prime Therapeutics, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 05:15 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Lewis T. Williams, Founder, Chief Executive Officer, President and Director.

Five Prime Therapeutics, Inc. Announces Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Cash Flow from Operating Activities Guidance for the Year 2014

Five Prime Therapeutics, Inc. announced earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported collaboration revenue of USD 4,981,000 against USD 3,549,000 a year ago. Loss from operations was USD 9,916,000 against USD 7,422,000 a year ago. Net loss was USD 9,866,000 against USD 7,274,000 a year ago. Basic and diluted net loss per common share was USD 0.46 against USD 5.82 a year ago. The increase in revenue was primarily due to USD 1.9 million in revenue recognized under Five Prime's immuno-oncology collaboration with BMS established in March 2014. The increase in net loss was primarily due to the advancement of FPA144 towards a fourth quarter 2014 IND submission and public company-related expenses, partially offset by an increase in collaboration revenue. For the six months, the company reported collaboration revenue of USD 8,527,000 against USD 6,524,000 a year ago. Loss from operations was USD 18,576,000 against USD 14,769,000 a year ago. Net loss was USD 18,510,000 against USD 14,321,000 a year ago. Basic and diluted net loss per common share was USD 0.92 against USD 11.55 a year ago. The company continues to expect full-year 2014 net cash used in operating activities to be less than USD 30 million.

Similar Private Companies By Industry

Company Name Region
Human BioSciences Inc. United States
StemCor Systems, Inc. United States
Stemgent, Inc. United States
Perlstein Lab PBC United States
Oncotide Pharmaceuticals Inc United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
March 19, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Five Prime Therapeutics, Inc., please visit www.fiveprime.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.